[
    [
        {
            "time": "2023-10-05",
            "original_text": "Novartis Claims It Overpaid Genentech $210M In Patent Licensing Pact",
            "features": {
                "keywords": [
                    "Novartis",
                    "Genentech",
                    "overpaid",
                    "patent",
                    "licensing",
                    "lawsuit"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "UPDATE 1-Novartis contends Roche 'unjustly enriched' itself with $210 mln in fees -lawsuit",
            "features": {
                "keywords": [
                    "Novartis",
                    "Roche",
                    "unjustly enriched",
                    "fees",
                    "lawsuit"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "Novartis contends Roche 'unjustly enriched' itself with $210 million in fees -lawsuit",
            "features": {
                "keywords": [
                    "Novartis",
                    "Roche",
                    "unjustly enriched",
                    "fees",
                    "lawsuit"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "Novartis fights Roche in $210 mln U.S. dispute over licensing fees",
            "features": {
                "keywords": [
                    "Novartis",
                    "Roche",
                    "dispute",
                    "licensing",
                    "fees"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]